May 12, 2022
Data from the POETYK PSO long-term extension (LTE) trial showed deucravacitinib was clinically effective and safe for treating adult patients with moderate-to-severe plaque psoriasis.
April 26, 2022
Jeffrey Stark, MD, discusses the latest bimekizumab and certolizumab pegol data presented at the 2022 American Academy of Dermatology annual meeting.
January 20, 2022
Deucravacitinib selectively binds to a unique pocket in the regulatory domain of TYK2 instead of the highly conserved active site of the catalytic domain,” investigators explained. “This leads to targeted inhibition of immune pathways that are central to psoriasis while limiting off-target effects.”
October 18, 2021
Jeffrey Stark, MD, discusses the recent studies, BE BRIGHT, BE SURE, and BE VIVID, in which investigators analyzed the impact bimekizumab had on patients with psoriasis.
March 18, 2021
Guselkumab is the first and only approved IL-23 inhibitor therapy used to treat adults with active PsA and moderate to severe plaque psoriasis (PsO). The medication showed efficacy in skin clearance and joint symptom relief and passed safety measures. Additionally, physical function, health-related quality of life, and resolution of enthesitis and dactylitis were confirmed through week 100.
October 02, 2020
Researchers writing in JAMA Dermatology report that latent tuberculosis infection previously assumed to be an adverse event as a result of treatment with secukinumab, is actually uncommon in patients with chronic systemic inflammatory conditions.
November 27, 2019
Children with inflammatory bowel disease, juvenile idiopathic arthritis, and chronic noninfectious osteomyelitis who were treated with TNF inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, say researchers recently writing in Arthritis Care & Research.
July 15, 2019
Patients with severe psoriasis are also at a significant increase for developing advanced liver fibrosis, new research shows
May 30, 2019
Psoriasis patients have a lower risk of serious infection with specific biologic and non-biologic medications than with methotrexate, based on new research results.
February 26, 2019
Biological therapies prescribed for rheumatic diseases may also reduce their long-term risks of cardiovascular diseases (CVD), new research shows.